
    
      Voluntary adult patients, who do not have persistent atrial fibrillation before mitral valve
      sugery will receive either intravenous corticosteroid or placebo on three postoperative days
      after mitral valve surgery. End points are atrial fibrillation onset or fullfilling the three
      days time limit. The study is double-blinded, randomized, prospective study and the aim is to
      recruite 240 patients. Patients are recruited from Oulu University Hospital, Finland, Kuopio
      University Hospital, Finland, Helsinki University Hospital, Finland, Turku University
      Hospital, Finland, Tampere Univerisity Hospital, Finland, Tartu University Hospital, Estonia,
      Tallinn Regionaalhaigla, Estonia and Liverpool Hospital, Sydney, Australia.
    
  